Effective January 1, 2026, CMS will apply the 36-month rule to all DMEPOS suppliers. If a majority ownership change occurs within 36 months of initial Medicare enrollment or a previous ownership change, the buyer cannot assume the supplier’s Medicare billing privileges. The supplier’s enrollment will be terminated, and the buyer must re-enroll as a new DMEPOS supplier and obtain accreditation.

CMS has also replaced the three-year accreditation cycle with mandatory annual reaccreditation surveys, increasing ongoing compliance costs.

Key M&A Implications

Transaction Friction Increases

  • Buyers must carefully review Medicare enrollment timelines. Acquiring a supplier within the 36-month window may result in billing disruptions during re-enrollment.

Valuation Divergence Emerges

  • Suppliers with established 36-month enrollment histories are significantly more valuable than newly enrolled suppliers. Anticipate reduced valuation multiples, inflated escrow structures, and earnouts contingent on successful enrollment.

Private Equity Roll-Ups Are Constrained

  • The rule is intended to limit rapid ownership turnover, which is common in private equity roll-up strategies. Secondary buyouts within the 36-month window will be more difficult to complete.

Deal Structuring Becomes Critical

  • Indirect ownership changes, such as acquiring a parent entity, may avoid triggering the rule. However, CMS may challenge aggressive structuring.

Multi-Location Platforms Are More Complex

  • Each DMEPOS location requires separate enrollment, so platform acquisitions may involve multiple 36-month timelines, increasing due diligence complexity.

Higher Ongoing Compliance Costs

  • Annual accreditation surveys introduce recurring regulatory costs and operational disruptions at each location.

Strategies Gain an Advantage

  • Strategic buyers with established compliance infrastructure are better equipped to manage re-enrollment risk than financial sponsors.

Bottom Line

The CMS rule introduces structural challenges to DMEPOS M&A, particularly for newer suppliers and recently acquired assets. Anticipate slower deal velocity, valuation discounts for suppliers within the 36-month window, and increased diligence regarding Medicare enrollment history.